Meaux, France

Jean Luc Perfettini


 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Jean Luc Perfettini

Introduction

Jean Luc Perfettini is a notable inventor based in Meaux, France. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Perfettini's work focuses on enhancing the efficacy of cancer therapies.

Latest Patents

Perfettini's latest patents include groundbreaking methods for reducing tumor growth and enhancing the effectiveness of radiation therapy. The first patent, titled "Use of Minaprine to Reduce Tumor Growth," involves the use of Minaprine dihydrochloride and its analogs to inhibit tumor growth in patients suffering from cancer. The second patent, "Enhancers of Cellular Cannibalism for Use to Sensitize Tumors to Radiation Therapy," describes compounds that enhance IR-mediated cellular cannibalism in cancer cells. These compounds aim to improve tumor immunogenicity and induce a protective anticancer immune response in patients undergoing radiotherapy.

Career Highlights

Jean Luc Perfettini is affiliated with the Institut Gustave Roussy, a leading cancer research institution. His work has been instrumental in advancing cancer treatment methodologies, particularly in the context of combining pharmacological agents with radiation therapy.

Collaborations

Perfettini collaborates with esteemed colleagues such as Eric Deutsch and Catherine Brenner, contributing to a multidisciplinary approach in cancer research and treatment.

Conclusion

Jean Luc Perfettini's innovative patents and collaborative efforts are paving the way for more effective cancer treatments. His research continues to inspire advancements in the medical field, particularly in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…